COMMUNIQUÉS West-GlobeNewswire
-
Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study
28/06/2018 - 15:00 -
Konica Minolta Launches Portable Ultrasound with One-touch Image Optimization for Improved Workflow and Diagnostic Efficiency
28/06/2018 - 15:00 -
BlissCo's International Cannabis Ecosystem Taking Shape -- CFN Media
28/06/2018 - 15:00 -
AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands
28/06/2018 - 15:00 -
XORTX Reports on Annual Special Meeting and Provides Corporate Update
28/06/2018 - 14:59 -
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation for Treatment of Burkitt Lymphoma, and Initiates a Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
28/06/2018 - 14:55 -
Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy
28/06/2018 - 14:45 -
Groupe Santé Devonian annonce la signature d’une lettre d’intention non contraignante avec Folia Biotech pour le développement du FB-631 en immunothérapie pour le cancer
28/06/2018 - 14:45 -
Grandevo® CG and Venerate® CG for Pest Insect and Mite Control Cleared for Use on Cannabis by the Colorado, Oregon, Washington, Nevada, and Alaska Departments of Agriculture
28/06/2018 - 14:31 -
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.
28/06/2018 - 14:30 -
Celsion Corporation Announces Strategic Loan Facility
28/06/2018 - 14:30 -
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immunotherapy
28/06/2018 - 14:30 -
International Endeavors Offers Equipment to Licensed Marijuana Growers
28/06/2018 - 14:30 -
GTX Corp Launches 2 New GPS Trackers for Kids SmartSole Now Available in Size Small
28/06/2018 - 14:14 -
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
28/06/2018 - 14:00 -
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
28/06/2018 - 14:00 -
BRACAnalysis® CDx Identifies Patients Who Respond to Lynparza® in SOLO-1 Study
28/06/2018 - 13:05 -
Amfora Unveils Broad Initiative to Develop Crops with Enhanced Protein Content for Food and Feed
28/06/2018 - 14:15 -
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
28/06/2018 - 14:00
Pages